Chemo Fog pp 1-10 | Cite as

Short Introduction and History

  • Robert B. Raffa
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 678)

Abstract

If one does a MEDLINE® search using as keywords chemo fog or chemo brain or their hyphenated equivalents, fewer than 30 ‘hits’ appear. The oldest dates back to 2003. This small number of hits in some way captures one aspect of the current state of the phenomenon (or phenomena). In contrast, if one does the search using ‘cognitive × cancer × chemotherapy’, hundreds more hits appear. This in some way captures another aspect of the phenomenon. It is both little-known and well-known. To go a step further, some data suggest that it is one of the most common adverse effects of chemotherapy, other data suggest that it does not exist. Even its name (or lack thereof) is still unsettled. Yet, patients consistently report it. This chapter introduces the reader to the fascinating and complex challenges—to patients, healthcare providers, basic scientists, employers, insurers and others—inherent in this topic and the current state of knowledge about it.

Keywords

Fatigue Depression Lymphoma Estrogen Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Amer J Psychiatry 1980; 137:597–601.Google Scholar
  2. 2.
    Packer RJ, Meadows AT, Rorke LB et al. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 1987; 15:241–253.PubMedCrossRefGoogle Scholar
  3. 3.
    Copeland DR, Dowell RE Jr, Fletcher JM et al. Neuropsychological effects of childhood cancer treatment. J Child Neurol 1988; 3:53–62.PubMedGoogle Scholar
  4. 4.
    Kramer J, Moore IM. Late effects of cancer therapy on the central nervous system. Seminars Oncol Nursing 1989; 5:22–28.CrossRefGoogle Scholar
  5. 5.
    Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park) 1990; 4:115–122.Google Scholar
  6. 6.
    Gamis AS, Nesbit ME. Neuropsychologic (cognitive) disabilities in long-term survivors of childhood cancer. Pediatrician 1991; 18:11–19.PubMedGoogle Scholar
  7. 7.
    van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210–218.PubMedCrossRefGoogle Scholar
  8. 8.
    Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Instit 1998; 90:182–183.CrossRefGoogle Scholar
  9. 9.
    Raffa RB, Duong PV, Finney J et al. Is ‘chemo-fog’/chemo brain caused by cancer chemotherapy? J Clin Pharm Ther 2006; 31:129–138.PubMedCrossRefGoogle Scholar
  10. 10.
    Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology 2001; 15:613–618.PubMedGoogle Scholar
  11. 11.
    Anderson-Hanley C, Sherman ML, Riggs R et al. Neuropsychological effect of treatments for adults with cancer: A meta-analysis and review of the literature. J Intl Neuropsychol Soc 2003; 9:967–982.CrossRefGoogle Scholar
  12. 12.
    Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 2003; 95:190–197.PubMedCrossRefGoogle Scholar
  13. 13.
    Tannock IF, Tim AA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233–2239.PubMedCrossRefGoogle Scholar
  14. 14.
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncol 1995; 4:61–66.CrossRefGoogle Scholar
  15. 15.
    Schagen S, van Dam F, Muller M et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640–650.PubMedCrossRefGoogle Scholar
  16. 16.
    Schagen SB, Muller MJ, Boogerd W et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Annals Oncol 2002; 13:1387–1397.CrossRefGoogle Scholar
  17. 17.
    Brezden C, Phillips K, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:2695–2701.PubMedGoogle Scholar
  18. 18.
    Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485–493.PubMedCrossRefGoogle Scholar
  19. 19.
    O’Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3(suppl 3):S116–S120.PubMedCrossRefGoogle Scholar
  20. 20.
    Tchen N, Juffs HG, Downie FP et al. Cognitive changes, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer: a prospective matched cohort study. J Clin Oncol 2003; 21:4175–4183.PubMedCrossRefGoogle Scholar
  21. 21.
    Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100:2292–2299.PubMedCrossRefGoogle Scholar
  22. 22.
    Meyers C. Neurocognitive dysfunction in cancer patients. Oncology 2000; 14:75–81.PubMedGoogle Scholar
  23. 23.
    Schagen SB, Hamburger HL, Muller MJ et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001; 51:159–165.PubMedCrossRefGoogle Scholar
  24. 24.
    Kingma A, van Dommelen RI, Mooyaart EL et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatrics 2001; 139:413–420.CrossRefGoogle Scholar
  25. 25.
    Kibiger G, Kirsh KL, Wall JR et al. My mind is as clear as it used to be: a pilot study illustrating the difficulties of employing a single-item subjective screen to detect cognitive impairment in outpatients with cancer. J Pain Symp Manage 2003; 26:705–715.CrossRefGoogle Scholar
  26. 26.
    Appleton RE, Farrell K, Zaide J et al. Decline in head growth and cognitive impairment in survivors of acute lymphoblastic leukemia. Arch Disease Childhood 1990; 65:530–534.CrossRefGoogle Scholar
  27. 27.
    Van Oosterhout AG, Ganzevles PG, Wilmink JT et al. Sequelae in long-term survivors of small cell lung cancer. Internatl J Rad Oncol Biol Phys 1996; 34:1037–1044.CrossRefGoogle Scholar
  28. 28.
    Ahles TA. Do systemic cancer treatments affect cognitive function? Lancet Oncol 2004; 5:270–271.PubMedCrossRefGoogle Scholar
  29. 29.
    Riva D, Giorgi C, Nichelli F et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 2002; 59:48–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Brown RT, Madan-Swain A, Walco GA et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J Ped Psychia 1998; 23:333–340.CrossRefGoogle Scholar
  31. 31.
    Shilling V, Jenkins V, Fallowfield L et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Molec Biol 2003; 86:405–412.PubMedCrossRefGoogle Scholar
  32. 32.
    Almeida OP, Flicker L. The mind of a failing heart: a systematic review of the association between congestive heart failure and cognitive functioning. Internal Med J 2001; 31:290–295.CrossRefGoogle Scholar
  33. 33.
    Allena KV, Frier BM, Strachan MWJ. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004; 490:169–175.CrossRefGoogle Scholar
  34. 34.
    Liesker JJ, Postma DS, Beukema RJ et al. Cognitive performance in patients with COPD. Resp Med 2004; 98:351–356.CrossRefGoogle Scholar
  35. 35.
    Antonelli Incalzi R, Marra C, Giordano A et al. Cognitive impairment in chronic obstructive pulmonary disease A neuropsychological and SPECT study. J Neurol 2003; 250:325–332.CrossRefGoogle Scholar
  36. 36.
    Wilson RS, Mendes de Leon CF, Bennett DA et al. Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychia 2004; 75:12126–12129.CrossRefGoogle Scholar
  37. 37.
    Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nursing Res 2001; 50:86–94.CrossRefGoogle Scholar
  38. 38.
    Wefel S, Lenzi R, Theriault R et al. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer 2004; 101:466–475.PubMedCrossRefGoogle Scholar
  39. 39.
    Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exper Neuropsychol 1985; 7:251–263.CrossRefGoogle Scholar
  40. 40.
    Holland J. New treatment modalities in radiation therapy. J Intravenous Nursing 2001; 24:95–101.Google Scholar
  41. 41.
    Noad R, Narayanan KR, Howlett T et al. Evaluation of effects of radiotherapy for pituitary tumors on cognitive function and quality of life. Clin Oncol Royal College Radiol 2004; 16:233–237.CrossRefGoogle Scholar
  42. 42.
    Keime-Guibert F, Napolitano M, Delattre J. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998; 245:695–708.PubMedCrossRefGoogle Scholar
  43. 43.
    Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Eng J Med 1976; 294:405–410.CrossRefGoogle Scholar
  44. 44.
    Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20 years follow-up. N Eng J Med 1995; 332:901–906.CrossRefGoogle Scholar
  45. 45.
    Harris J. Morrow M, Norton L. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers, 1997; 2:1541–1616.Google Scholar
  46. 46.
    Kemper E, Boogerd W, Thuis I et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004; 30:415–423.PubMedCrossRefGoogle Scholar
  47. 47.
    Neuwelt EA, Barnett P, Barranger J et al. Inability of dimethyl sulfoxide and 5-fluorouracil to open the blood-brain barrier. Neurosurgery 1983; 12:29–34.PubMedCrossRefGoogle Scholar
  48. 48.
    MacDonell LA, Potter PE, Leslie RA. Localized changes in blood-brain barrier permeability following the administration of antineoplastic drugs. Cancer Res 1978; 38:2930–2934.PubMedGoogle Scholar
  49. 49.
    Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie 2002; 25:474–479.PubMedCrossRefGoogle Scholar
  50. 50.
    Neuwelt EA, Barnett PA, Frenkel EP. Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery 1984; 14:154–160.PubMedCrossRefGoogle Scholar
  51. 51.
    Fliessbach K, Urbach H, Helmstaedter C et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous System lymphoma. Arch Neurol 2003; 60:563–568.PubMedCrossRefGoogle Scholar
  52. 52.
    Caine GJ, Stonelake PS, Rea D et al. Coagulopathic complications in breast cancer. Cancer 2003; 98:1578–1586.PubMedCrossRefGoogle Scholar
  53. 53.
    Love S. Chemobrain/Cognitive Dysfunction. The Website for Women. http://www.susanlovemd.org/faq/ chemobrain/chemobrain.htmllGoogle Scholar
  54. 54.
    Foreman J. “Chemo Brain” Leaves Patients at a Loss. Health Sense Columns 2003, http://www.myhealthsense. com/F030701_Chemo.htmlGoogle Scholar
  55. 55.
    Madhyastha S, Somayaji SN, Rao MS et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Canad J Physiol Pharmacol 2002; 80:1076–1084.CrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Robert B. Raffa
    • 1
  1. 1.Department of Pharmaceutical SciencesTemple University School of PharmacyPhiladelphiaUSA

Personalised recommendations